Skip Navigation

Rapid Responses, Few Adverse Effects Seen with Targeted Agent in Phase 1 Trial in Rare Blood Disorder

Daniel DeAngelo, MD, PhD
December 10, 2017
In a Phase 1 trial, patients with an advanced or aggressive form of systemic mastocytosis (AdvSM), a rare blood disorder, had rapid and durable responses with few adverse effects following treatment with an investigational drug that targets the genetic mutation found in more than 90 percent of...
Read Story
  • Explore the Newsroom

    News Releases

    News releases about cancer care, cancer research, and cancer treatment by Dana-Farber Cancer Institute doctors and researchers.

    News Coverage

    Get the latest news about Dana-Farber Cancer Institute. 

    Publications

    Read the latest issues of Dana-Farber publications.

    Dana-Farber Spotlight

    Sign up to receive Dana-Farber Spotlight, our email newsletter.
    View the current issue
    Subscribe now
    Unsubscribe from mailings

    Insight Blog

    Insight features the latest in cancer care and research news from Dana-Farber.

    For Journalists

    Dana-Farber welcomes the opportunity to partner with journalists. Find contacts, resources, and more. 
  • View Our Events Calendar

    View Dana-Farber's calendar of events, including nutrition seminars, health and wellness classes, patient education, community outreach and fundraising events, and support groups.

    caregiver support group


    Participants in a caregiver support group